CoChat

Give the Receptor a Brake: Slowing Gastric Emptying by GLP-1

Open access
Tong, Jenny, D’Alessio, David · 2014 · Diabetes
Cited by 63

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

The conventional view of endocrinologists is that glucose regulation after a meal depends on the interplay of insulin and glucagon secretion, hepatic glucose production, and glucose disposal. However, in recent years the role of gastric motility and its effect on glucose appearance from the gut have been revived as a determinant of glucose tolerance (1,2). This is due in great part to the availability of diabetes therapeutics that act, in part, by delaying gastric emptying (GE). Yet it is important to note that much of the variance in oral glucose tolerance is accounted for by differences in GE rate, an observation made over two decades ago (1). Even a minor perturbation in GE carries a substantial impact on postprandial glycemia in healthy individuals (1) and those with diabetes (3), such that more rapid GE results in a greater initial glycemic response and slower gastric delivery of meal contents to the intestine leads to smaller glucose excursion (4). Glucagon-like peptide 1 (GLP-1) normalizes glycemia by promoting glucose-dependent insulin secretion and inhibiting glucagon secretion in the fasting state (5). A deceleration of GE is also characteristic of GLP-1 action and occurs both in patients with type 2 diabetes (T2D) and healthy individuals (6–8). In fact, glucose lowering by GLP-1 was significantly attenuated when the actions on GE were overridden by treatment with erythromycin (9). This has led to questions as to whether islet or gastrointestinal effects of GLP-1 predominate in its effects on glycemia (10). Long-acting GLP-1 receptor (GLP-1R) agonists, recently developed and now commonly used in the treatment of T2D, stimulate insulin secretion and reduce GE (5), but the relative impact of these two physiologic actions on acute and chronic control of blood glucose is not clear. Recent studies have raised the …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db13-1764

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 14

  1. Vella, 2004, The gastrointestinal tract and glucose tolerance, Curr Opin Clin Nutr Metab Care, 7, 479, 10.1097/01.mco.0000134375.01310.97 · DOI
  2. Jones, 1995, Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus, J Nucl Med, 36, 2220
  3. Gonlachanvit, 2003, Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients, Dig Dis Sci, 48, 488, 10.1023/A:1022528414264 · DOI
  4. Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am J Physiol, 273, E981
  5. Meier, 2003, Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes, J Clin Endocrinol Metab, 88, 2719, 10.1210/jc.2003-030049 · DOI · Paper page
  6. Nauck, 1999, Is glucagon-like peptide 1 an incretin hormone?, Diabetologia, 42, 373, 10.1007/s001250051165 · DOI
  7. Rao, 2011, Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies, Neurogastroenterol Motil, 23, 8, 10.1111/j.1365-2982.2010.01612.x · DOI · Paper page
  8. Nauck, 1993, Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations, J Clin Endocrinol Metab, 76, 912
  9. Holmes, 2009, Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions, J Physiol, 587, 4749, 10.1113/jphysiol.2009.175067 · DOI · Paper page
  10. Wettergren, 1998, Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow, Am J Physiol, 275, G984
  11. Plamboeck, 2013, The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty, Am J Physiol Gastrointest Liver Physiol, 304, G1117, 10.1152/ajpgi.00035.2013 · DOI · Paper page
  12. Broide, 2013, GLP-1 receptor is expressed in human stomach mucosa: analysis of its cellular association and distribution within gastric glands, J Histochem Cytochem, 61, 649, 10.1369/0022155413497586 · DOI
  13. Klemenska, 2009, Bioactivation of organic nitrates and the mechanism of nitrate tolerance, Cardiol J, 16, 11
  14. Henry, 2013, Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes, Diabetes Care, 36, 2559, 10.2337/dc12-2410 · DOI · Paper page

Cited by

See all 63

Metadata

Authors
Tong, J., & D’Alessio, D.
Venue
Diabetes
Published
2014-01-16
Volume
63
Issue
2
Pages
407-409
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2081436875
Cited by
63
References
11
FWCI
2.39
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Give the Receptor a Brake: Slowing Gastric Emptying by GLP-1. https://app.cochat.ai/papers/10.2337/db13-1764
The paper
Tong, J., & D’Alessio, D. (2014). Give the Receptor a Brake: Slowing Gastric Emptying by GLP-1. Diabetes. https://doi.org/10.2337/db13-1764

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.